Takeda (NYSE: TAK) R&D head sells 19,651 ADS under 10b5-1 plan

Rhea-AI Filing Summary

TAKEDA PHARMACEUTICAL CO LTD (TAK) director and officer Andrew Stewart Plump, President, R&D, reported the sale of 19,651 American Depositary Shares of Takeda on August 19, 2026 at $18.49 per ADS. The shares were held indirectly by a trust, which held 261,656 ADS afterward. Separately, Plump reported 766,569 ADS held directly following the reported transactions. The sale was effected under a Rule 10b5-1 trading plan adopted on May 15, 2026.

Insider Trade Summary 10b5-1

Net Seller: 19,651 shares

Net Sell 2 txns

Insider Plump Andrew Stewart

Role President, R&D

Sold 19,651 shs ($363K)

Type	Security	Shares	Price	Value
Sale	American Depositary Shares F1	19,651	$18.49	$363K
holding	American Depositary Shares	--	--	--

Holdings After Transaction: American Depositary Shares — 261,656 shares (Indirect, By Trust); American Depositary Shares — 766,569 shares (Direct)

Footnotes (1)

1. F1. The sales reported herein were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 15, 2026.

Key Figures

Shares sold: 19,651 American Depositary Shares Sale price: $18.49 per American Depositary Share Indirect holdings after sale: 261,656 American Depositary Shares +1 more

4 metrics

Shares sold 19,651 American Depositary Shares Non-derivative sale on August 19, 2026

Sale price $18.49 per American Depositary Share Price for the 19,651 ADS sold on August 19, 2026

Indirect holdings after sale 261,656 American Depositary Shares ADS held indirectly by trust following the reported sale

Direct holdings after transactions 766,569 American Depositary Shares ADS held directly by Andrew Stewart Plump after reported transactions

Key Terms

American Depositary Shares, Rule 10b5-1 plan, indirect ownership

3 terms

American Depositary Shares financial

"security_title: "American Depositary Shares""

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

Rule 10b5-1 plan regulatory

"The sales reported herein were effected pursuant to a Rule 10b5-1 plan"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

indirect ownership financial

"ownership_type: "indirect" with nature_of_ownership "By Trust""

FAQ

What insider transaction did TAK (Takeda Pharmaceutical Co Ltd) report for Andrew Stewart Plump?

Andrew Stewart Plump reported a sale of 19,651 American Depositary Shares of Takeda on August 19, 2026. The sale price was $18.49 per ADS, and the shares were held indirectly by a trust associated with him.

At what price were the Takeda (TAK) shares sold in this Form 4 filing?

The reported sale of Takeda (TAK) shares was executed at a price of $18.49 per American Depositary Share. This price applies to the 19,651 ADS sold on August 19, 2026 in an open market or private transaction.

How many Takeda (TAK) shares does the trust hold after the reported sale?

After the reported transaction, the trust associated with Andrew Stewart Plump held 261,656 American Depositary Shares of Takeda. These shares are reported as indirect ownership by trust following the sale of 19,651 ADS.

What is Andrew Stewart Plump’s direct shareholding in Takeda (TAK) after the transactions?

Following the reported transactions, Andrew Stewart Plump reported 766,569 American Depositary Shares of Takeda held directly. This direct holding is separate from the 261,656 ADS held indirectly through a trust.

Was the Takeda (TAK) insider sale made under a Rule 10b5-1 plan?

Yes. The filing states that the sales were effected pursuant to a Rule 10b5-1 plan adopted by Andrew Stewart Plump on May 15, 2026, and the form’s Rule 10b5-1 checkbox is marked as affirmed.

Who is the insider involved in this Takeda (TAK) Form 4 and what is his role?

The insider is Andrew Stewart Plump, who serves as a director and as President, R&D of Takeda Pharmaceutical Co Ltd. He reported both an indirect sale by trust and his resulting direct and indirect shareholdings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/21/2026 - 04:31 PM Accepted by SEC EDGAR 08/21/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Plump Andrew Stewart

(Last) (First) (Middle)

300 MASSACHUSETTS AVE.

(Street)

CAMBRIDGE MASSACHUSETTS 02139

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TAKEDA PHARMACEUTICAL CO LTD [ TAK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, R&D

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
American Depositary Shares	08/19/2026		S(1)		19,651	D	$18.49	261,656	I	By Trust
American Depositary Shares								766,569	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported herein were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 15, 2026.

	/s/ Samuel Ntonme, by power of attorney, for Andrew S Plump	08/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)